Local Injection of Novel Immunotherapy Triggers Systemic Tumor Regression

Researchers at Rockefeller University have developed a novel CD40 agonist antibody, 2141-V11, which has yielded remarkable results in a Phase 1 clinical trial. Administered directly into tumors, rather than intravenously, the drug significantly reduced side effects. Of 12 patients with metastatic cancer, six saw tumor shrinkage, with two achieving complete remission – meaning their cancer disappeared entirely. Remarkably, this localized injection triggered a systemic immune response capable of eliminating tumors elsewhere in the body. This research offers new hope for cancer immunotherapy, and further studies will explore the mechanism of action and patient selection criteria to improve efficacy.